Slide 1: Transforming health through the human microbiome
or personal use only Transforming health through the human microbiome January 2023 | Authorised for release by the CEO & Chairman
Slide 2: Disclaimer
Disclaimer This presentation (Presentation) has been prepared by Microba Life Sciences Limited (Microba). Summary information - This Presentation contains summary information about Microba and its activities which is current only as at the date of release of this Presentation. Microba may in its abs
Slide 3: Two core business segments driven by a proprietary databank
Two core business segments driven by a proprietary databank or personal use only Services Databank Therapeutics Proprietary databank Data Insights Health Data Customer Novel Testing Biome Data Therapies Microba provides testing Data-driven therapeutics and data analysis for a fee Driving discovery o
Slide 4: Company Snapshot
Company Snapshot or personal use only Continuous YoY Partnerships with market leaders Large, unique, proprietary revenue growth over incl. SYNLAB (GR:SYAB), microbiome databank 5 years of operations Sonic Healthcare (ASX: SHL), Genova Diagnostics, and G42 3 key therapeutic programs World-leading tec
Slide 5: Microbiome Services
or personal use only Microbiome Services Driving global revenues and data growth 5
Slide 6: Testing Services - Key Q2 FY23 Milestones
Testing Services - Key Q2 FY23 Milestones or personal use only STRATEGIC INVESTMENT & PARTNERSHIP Positive progress in distribution relationship with Sonic federation companies. Stage 1 Germany and Australia. ITALY & PORTUGAL SIGNED & COMMENCED Signed, commenced and first sales already achieved in I
Slide 7: Microba's leading international bench of healthcare partners
Microba’s leading international bench of healthcare partners or personal use only $9.3bn Revenue $5.8bn Revenue Partnership: UK, Germany, Leading GI Diagnostics in US Raised USD $800m Partnership: Europe Belgium, Australia, US, Partnership: US Partnership: GCC Region & LATAM NZ & Switzerland Microba
Slide 8: Significant international distribution expansion for Microba's testing services
Significant international distribution expansion for Microba’s testing services or personal use only Access into 35 countries Operations only activated in 7 of 35 countries Significant growth prospects ahead Coloured map depicts countries with binding distribution terms, and additional countries pla
Slide 9: Accelerating expansion and adoption
Accelerating expansion and adoption # Distributors # Countries Operational or personal use only Leading bench Launch & Early Major Market Further Country of healthcare COVID-19 Period partners provides Adopters Partnerships Expansion 12 access into 35 countries 10 Staged rollout to be executed to 8
Slide 10: Sonic Healthcare – Global Distribution Partnership
Sonic Healthcare – Global Distribution Partnership Stage 1 - Germany and Australia distribution or personal use only Sonic federation company engagement progressing well • Founded in 1934 Staged approach • $16B market cap - second largest healthcare - Stage 1 – Germany & Australia company on ASX
Slide 11: SYNLAB – Europe & LATAM Distribution Partnership
SYNLAB – Europe & LATAM Distribution Partnership Country expansion or personal use only Italy & Portugal signed • Founded 1998 Italy important territory – 3rd largest • Europe's largest medical diagnostics provider probiotics market in the world • $5.7B in revenues in FY22 • Employs around 30,00
Slide 12: Microbiome Therapeutics
or personal use only Microbiome Therapeutics Developing novel monoclonal microbial cell therapies 12
Slide 13: Repeatable, scalable, data-driven platform discovering novel monoclonal microbial cell therapies
Repeatable, scalable, data-driven platform discovering novel monoclonal microbial cell therapies or personal use only Monoclonal Population Identify AI & Advanced Disease microbial testing groups Biostatistics Models drug lead Healthy Orally administered, healthy Disease human donor derived, monoclo
Slide 14: Therapeutics - Key Q2 FY23 Milestones
Therapeutics - Key Q2 FY23 Milestones or personal use only MANUFACTURING THROUGH TO FDA PRE-IND MEETING POSITIVE DRUG PRODUCT OUTCOME MAP 315 engineering production • Positive formal feedback from the through to full encapsulated drug FDA on Pre-IND briefing book and product. pre-clinical package. •
Slide 15: Key milestones executed advancing to first in human clinical trial
Key milestones executed advancing to first in human clinical trial or personal use only Inflammatory Bowel Disease Cancer Immunotherapy Autoimmune Diseases PROGRESSING TO PHASE I PRECLINICAL SCREENING Recently Completed Recently Completed Recently Completed Manufacturing scale up Leads discovere
Slide 16: The start of a therapeutic revolution
The start of a therapeutic revolution or personal use only APPROVED 30 Nov 2022 Feacal doner derived enema drug product RECENT FDA APPROVAL HAS CLEARED THE PATH TO MARKET 26 April PDUFA date for FOR LIVE MICROBIOME DRUGS, anticipated FDA approval Feacal doner derived oral A NEW MODALITY. capsule dru
Slide 17: Outlook
or personal use only Outlook 17
Slide 18: Upcoming Milestones for FY23
Upcoming Milestones for FY23 2023 2023 or personal use only JAN - MAR APR - JUN Services New healthcare product full launch Services New international distribution deals Therapeutics - IBD MAP315 program Phase 1 HREC Submission Therapeutics - IBD MAP315 program FDA Pre-IND meeting outcome Services N
Slide 19: Contact
Contact or personal use only Dr Luke Reid Chief Executive Officer luke.reid@microba.com Head Office Level 10, 324 Queen Street Brisbane QLD Australia Pasquale Rombola Laboratory Princess Alexandra Hospital Chairman Woolloongabba QLD Australia pasquale.rombola@microba.com